Transforming Vision Care for Millions Worldwide
Normal Vison
AMD Patient
At Orsight Pharma, we are committed to developing innovative therapies that address the major unmet needs in neovascular Age-related Macular Degeneration (nAMD). Our approach targets broader biological pathways beyond VEGF, aiming to deliver durable visual outcomes and a better quality of life for millions.
Normal Vison
AMD Patient
Up to 50% of patients show insufficient response.
Current therapies target only VEGF and Ang2 missing key pathways.
years
Mean vision gains start to decline after 3 years of treatment
Despite advances, up to 50% of patients with nAMD show inadequate responses to existing anti-VEGF therapies. Mean visual acuity declines within three years of treatment, and most patients experience persistent disease activity. A new therapeutic strategy is urgently needed to overcome these limitations.
Orsight’s small molecule therapy targets a VEGF-independent anti-angiogenic pathway, offering a first-in-class approach to suppress neovascularization and reduce edema. Designed for chronic use, it combines superior tissue penetration, low immunogenicity, and compatibility with slow-release systems to maximize durability and patient compliance. Our therapy holds the promise of redefining long-term management for patients with nAMD.
Targeting broader angiogenic pathways beyond VEGF.
Preclinical studies demonstrate strong efficacy and safety.
Neovascular Age-related Macular Degeneration (nAMD) represents a major and growing public health challenge. Today, over 1.5 million Americans are affected, with ~300,000 new cases diagnosed each year, and the number of legally blind patients is projected to double by 2050. The global nAMD market is projected to grow from $8.4 billion in 2023 to $14.4 billion by 2030, reflecting an 8% CAGR and a strong unmet need for new therapies.
Americans currently affected by nAMD
Strong Commercial Opportunity
New cases diagnosed each year
Global Market Growth (2023–2030)
Orsight Pharma is redefining the future of retinal disease treatment. If you are interested in learning more, collaborating, or investing in our breakthrough therapies, we invite you to get in touch.
Orsight Pharma combines scientific innovation with clinical expertise to redefine retinal disease treatment and drive long-term impact.
Copyright © 2025 | Powered by Little Prince Digital
Privacy Policy | Our Terms
